Showing results (101-110 of 137) with videos related to

Sort By:
Pageof 14
BMJ Open|November 11, 2020
Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series studyEva Jiménez, Mario Fontán-Vela, Jorge Valencia, et al.
Journal of Clinical Medicine|July 9, 2022
Dynamics of HIV Reservoir and HIV-1 Viral Splicing in HCV-Exposed Individuals after Elimination with DAAs or Spontaneous ClearancePaula Martínez-Román, Celia Crespo-Bermejo, Daniel Valle-Millares, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 TrialFederico Pulido, Esteban Ribera, María Lagarde, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 15, 2021
HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterizationDaniel Valle-Millares, Óscar Brochado-Kith, Alicia Gómez-Sanz, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|March 12, 2021
Impact of Systemic Corticosteroids on Mortality in Older Adults With Critical COVID-19 PneumoniaEsther Piniella-Ruiz, María Teresa Bellver-Álvarez, Beatriz Mestre-Gómez, et al.
Scientific Reports|April 5, 2019
HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional studyMaria Rosa López-Huertas, Claudia Palladino, Marta Garrido-Arquero, et al.
Open Forum Infectious Diseases|November 28, 2025
Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022-2024)Pablo Ryan, Juan Berenguer, Luis Ramos-Ruperto, et al.
Plos One|January 20, 2026
Correction: Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trialSergio Sequera-Arquelladas, María J Vivancos, David Vinuesa, et al.
Plos One|September 22, 2025
Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trialSergio Sequera-Arquelladas, María J Vivancos, David Vinuesa, et al.
International Journal of Antimicrobial Agents|April 4, 2024
Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trialCarmen Hidalgo-Tenorio, Sergio Sequera, María Jesus Vivancos, et al.
Pageof 14